AstraZeneca's Ambition 2030 Strategy

@financepresentations

7 Followers

1 week ago 43

Business #Pharmaceuticals #FinancialForecast #InvestorDay #HealthcareLeadership #AstraZeneca

Explore AstraZeneca's ambitious plans for growth and innovations through 2030. The emphasis is on harnessing science and technology to enhance patient outcomes while navigating risks in a competitive landscape. Insights from AstraZeneca's investor day outline financial targets and strategic initiatives that aim for sustainability and leadership in emerging markets. Join for a look into the future of medicine.

AstraZeneca's Ambition 2030 Strategy

@financepresentations1 week ago

Ambition 2030 and beyond

Pascal Soriot, CEO

Forward looking statements

In order, among other things, to utilise the 'safe harbour' provisions of the US Private Securities Litigation Reform Act of 1995, AstraZeneca (hereafter 'the Group') provides the following cautionary statement: This document contains certain forward-looking statements with respect to the operations, performance and financial condition of the Group, including, among other things, statements about expected or targeted revenues, margins, earnings per share or other financial or other measures (including the Financial Ambition Statements described in this presentation). Although the Group believes its expectations and targets are based on reasonable assumptions and has used customary forecasting methodologies used in the pharmaceutical industry and risk-adjusted projections for individual medicines (which take into account the probability of success of individual clinical trials, based on industry-wide data for relevant clinical trials at a similar stage of development), any forward-looking statements, by their very nature, involve risks and uncertainties and may be influenced by factors that could cause actual outcomes and results to be materially different from those predicted. The forward-looking statements reflect knowledge and information available at the date of preparation of this document and the Group undertakes no obligation to update these forward-looking statements. The Group identifies the forward-looking statements by using the words 'anticipates', 'believes', 'expects', 'intends' and similar expressions in such statements. Important factors that could cause actual results to differ materially from those contained in forward-looking statements, certain of which are beyond the Group's control, include, among other things: the risk of failure or delay in delivery of pipeline or launch of new medicines; the risk of failure to meet regulatory or ethical requirements for medicine development or approval; the risk of failures or delays in the quality or execution of the Group's commercial strategies; the risk of pricing, affordability, access and competitive pressures; the risk of failure to maintain supply of compliant, quality medicines; the risk of illegal trade in the Group's medicines; the impact of reliance on third-party goods and services; the risk of failure in information technology or cybersecurity; the risk of failure of critical processes; the risk of failure to collect and manage data in line with legal and regulatory requirements and strategic objectives; the risk of failure to attract, develop, engage and retain a diverse, talented and capable workforce; the risk of failure to meet regulatory or ethical expectations on environmental impact, including climate change; the risk of the safety and efficacy of marketed medicines being questioned; the risk of adverse outcome of litigation and/or governmental investigations; intellectual property-related risks to the Group's products; the risk of failure to achieve strategic plans or meet targets or expectations; the risk of failure in financial control or the occurrence of fraud; the risk of unexpected deterioration in the Group's financial position; the impact that global and/or geopolitical events may have, or continue to have, on these risks, on the Group's ability to continue to mitigate these risks, and on the Group's operations, financial results or financial condition There can be no guarantees that the conditions to the closing of the proposed transaction with Fusion will be satisfied on the expected timetable, or at all, or that 'FPI-2265' (Ac225-PSMA I&T) or any combination product will receive the necessary regulatory approvals or prove to be commercially successful if approved. There can be no guarantees that the conditions to the closing of the proposed transaction with Amolyt Pharma will be satisfied on the expected timetable, or at all, or that eneboparatide ('AZP-3601') will receive the necessary regulatory approvals or prove to be commercially successful if approved.

This presentation includes references to new molecular entities and life-cycle management programmes that are being investigated in current or future clinical trials, and as such have not been approved by any regulatory agency. For a list of new molecular entities and indications in development, see pages 7-11 of the Clinical Trials Appendix that accompanied AstraZeneca's Q1 2024 results.

Basis of AstraZeneca ambitions, forecasts and targets

AstraZeneca ambitions, forecasts and targets in this presentation (the 'Financial Ambition Statements') are derived from AstraZeneca's most recent risk-adjusted mid- and long-term plans, adjusted for developments in the business since those plans were finalised. Financial Ambition Statements presented are based on management's risk-adjusted projections for individual medicines and individual clinical trials. Estimates for these probabilities are based on industry-wide data for relevant clinical trials in the pharmaceutical industry at a similar stage of development adjusted for management's view on the risk profile of the specific asset. The peak year revenue (PYR) potential for individual medicines referred to in this presentation are the maximum estimated Total Revenue to be recognised by AstraZeneca in a single calendar year, during the lifecycle of the medicine, and are based on management's latest non-risk adjusted forecast estimates. Estimates are based on customary forecasting methodologies used in the pharmaceutical industry. Peak year revenue may occur in different years for each NME depending on trial outcomes, approval label, competition, launch dates and exclusivity periods, amongst other variables. The peak year revenue figures are derived from net sales at nominal values and are not risk-adjusted or time-value discounted. The development of pharmaceutical products has inherent risks given scientific experimentation and there are a range of possible outcomes in clinical results, safety, efficacy and product labelling. Clinical results may not achieve the desired product profile and competitive environment, pricing and reimbursement may have material impact on commercial revenue forecasts. By their nature, forecasts are based on a multiplicity of assumptions and actual performance in future years may vary, significantly and materially, from these assumptions. The Financial Ambition Statements in this presentation are based on Q1 2024 exchange rates; AZ undertakes no obligation to update those statements based on future currency movements

We delivered on our Total Revenue ambition set in 2014

From 2017 to 2023 AstraZeneca is targeting strong and consistent revenue growth leading to annual revenues of greater than $45 billion by 2023 ' '

Press release issued 06 May 2014 1

Our strategy is consistent but dynamic

Science & innovation

Â· Invest in new technologies and modalities
Â· Leverage global R&D network

Growth & therapy area leadership

Â· Transform patient outcomes through novel medicines and combinations

Global footprint

Sustainability

Â· Broad-based network
Â· Differentiated Emerging Markets presence
Â· Expand access, build health system resilience
Â· Drive industry-leading climate agenda

5 strategic R&D centres across Europe, US and China

Cambridge, UK

Gothenburg, Sweden

Gaithersburg, MD

Boston, MA - Kendall Square

Strategic R&D centre locations enable academic collaborations and ability to attract top-tier global talent

Shanghai, China

Strong, sustained pipeline delivery supports upgraded NME launch ambition

Clear momentum, now expect to

Launch 20 NMEs by 2030 1

On track to achieve ambition with six NMEs already launched

Now we have a new ambition to deliver $80bn in Total Revenue by 2030 with sustained growth thereafter

On track to deliver mid-30s% Core operating margin by 2026

Beyond 2026, Core operating margin will be influenced by portfolio evolution, and the Company will target at least mid-30s%

Investor Day

Â·

2024

Investor Day

Â·

2024

Ambition - $80bn Total Revenue by 2030 and sustained 2030+ growth Working on 'today, tomorrow and the day after'

Beyond 2030

Note: Ambition to achieve $80bn in Total Revenue by 2030 is risk-adjusted, based on latest long-range plan - see 'Forward looking statements' slide for forward looking statement.. Medicines and assets listed reflect key contributors to 2030 Total Revenue ambition; however, this list is not exhaustive. Medicines and assets listed in alphabetical order and sorted by therapy area. 1. Amolyt Pharma acquisition remains subject to customary external clearances; all clinical development plans mentioned herein subject to deal closure.

Collaboration partners: Daiichi Sankyo (

Enhertu

, Dato-DXd), Amgen (

Tezspire

), Ionis (

Wainua

), Compugen (rilvegostomig), Merck & Co., Inc. (

Lynparza).

Acronym definitions can be found in Glossary.